Please confirm that you would like to log out of Medscape.
If you log out, you will be required to enter your username and password the next time you visit.
Log outCancel
European Society of Cardiology (ESC) Congress 2020
August 29 - September 01, 2020; Virtual
August 29 - September 01, 2020Virtual
Meeting Highlights At A Glance
ESC 2020 Highlights: Drugs Old and NewTop trials from the virtual ESC 2020 featured old drugs such as aspirin and colchicine as well as the new SGLT2 inhibitors.
ESC 2020 Highlights: Treatment Strategies & the Virtual ExperienceThe first randomized trial on stopping ACE inhibitors and ARBs in patients with COVID-19, and a comparison of rhythm vs rate
control in AF are among the strategies tested in trials presented at ESC 2020.
PARAGON-HF: Sacubitril/Valsartan Frustrates in Preserved-EF HFHopes were the trial would provide something new: solid clinical trial backing for an HFpEF drug therapy. It didn't, but some
say it supports consideration of the drug in at least one HFpEF subgroup.
Medscape Medical News, Sep 01, 2019
Dapagliflozin: New HF Therapy, Even Sans DiabetesSignificant reductions in heart failure events and mortality associated with the diabetes drug in the randomized trial point
to a new era in the treatment of heart failure, experts say.
Medscape Medical News, Sep 01, 2019
COMPLETE: Better Outcome With PCI in Nonculprit Lesions After STEMINew data show intervention in nonculprit lesions after STEMI in patients with multivessel disease reduced CV death, recurrent
MI, and ischemia-driven revascularization vs a culprit-lesion-only strategy.